Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

42.40 -1.18 (-2.71%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans ↗
Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts shaped the update. 
Via Benzinga
News headline image
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Exelixis Q2 Revenue Falls 11 Percent ↗
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Peering Into Exelixis's Recent Short Interest ↗
 
Via Benzinga
News headline image
Peering Into Exelixis's Recent Short Interest ↗
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
EXELIXIS INC (NASDAQ:EXEL): A Prime Example of Affordable Growth in Biotech ↗
EXELIXIS (NASDAQ:EXEL) offers strong growth, fair valuation, and financial health, fitting the "Affordable Growth" strategy with high scores in profitability and low bankruptcy risk. 
Via Chartmill
Topics Bankruptcy
News headline image
Uncovering Potential: Exelixis's Earnings Preview ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 28, 2025 ↗
 
Via Benzinga
News headline image
EXELIXIS INC (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Breakout Potential ↗
EXELIXIS INC (EXEL) combines strong growth fundamentals—high profitability, solid financials, and rising revenue—with bullish technical signals, making it a promising breakout candidate for investors. 
Via Chartmill
News headline image
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
News headline image
EXELIXIS INC (NASDAQ:EXEL) – A High-Growth Momentum Stock with Strong Technical Setup ↗
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors and breakout traders. 
Via Chartmill
News headline image
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner ↗
Via The Motley Fool
News headline image
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in High-Growth Oncology Stocks ↗
EXELIXIS (NASDAQ:EXEL) shows strong technical and fundamental growth, meeting Minervini’s Trend Template criteria with high earnings momentum and a bullish chart setup. 
Via Chartmill
News headline image
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. ↗
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
From Exelixis, Inc.
Via Business Wire
News headline image
Assessing Exelixis: Insights From 12 Financial Analysts ↗
 
Via Benzinga
News headline image
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors ↗
EXELIXIS INC (NASDAQ:EXEL) shows strong growth, profitability, and financial health, making it a standout for investors following Louis Navellier’s strategy. With high earnings surprises and... 
Via Chartmill
News headline image
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation ↗
EXELIXIS INC (NASDAQ:EXEL) offers strong growth potential at a reasonable valuation, backed by solid profitability and a debt-free balance sheet. A compelling pick for growth investors. 
Via Chartmill
News headline image
2 Stocks to Buy With Less Than $50 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
EXELIXIS INC (NASDAQ:EXEL) - An Undervalued Biotech Stock With Strong Fundamentals ↗
EXELIXIS (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, zero debt, and robust growth prospects, making it a candidate for value investors. 
Via Chartmill
News headline image
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Technical Breakout Potential ↗
EXELIXIS (NASDAQ:EXEL) is a strong growth stock with breakout potential, backed by robust earnings, revenue growth, and a healthy technical setup. 
Via Chartmill
News headline image
3 No-Brainer Stocks to Buy for Under $100 Right Now ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
EXELIXIS INC (NASDAQ:EXEL) – A High Growth Momentum Stock with Strong Technical Setup ↗
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors. The stock is consolidating with clear support... 
Via Chartmill
News headline image
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Growth and Momentum Investing ↗
EXELIXIS INC (NASDAQ:EXEL) shows strong growth momentum and meets Minervini’s trend criteria, making it a stock to watch for high-growth investors. 
Via Chartmill
News headline image
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug ↗
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug. 
Via Investor's Business Daily
News headline image
Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.